Skip to main content

Table 2 Survival time in relation to patient characteristics

From: Hypernatremia at admission predicts poor survival in patients with terminal cancer: a retrospective cohort study

 

n

Median survival, days (95% CI)

Pb

Age, years

  < 70

232

29 (13–52)

0.003

  ≥ 70

255

24 (14–40)

 

Sex

 Female

219

29 (13–48)

0.035

 Male

268

24 (14–40)

 

Cancer site

 Gastrointestinal tract

127

29 (14–47)

0.012

 Hepatobiliary/pancreatic

118

24 (13–33)

 

 Lung

108

22 (12–41)

 

 Urogenital tract

57

27 (13–55)

 

 Others

77

35 (19–47)

 

ECOG-PS

  ≤ 2

115

30 (18–50)

0.012

 3

189

27 (14–48)

 

 4

183

23 (11–40)

 

Active infection

 No

322

27 (12–46)

0.558

 Yes

164

25 (14–38)

 

Leukocytosis

 No

279

31 (15–52)

< 0.001

 Yes

208

22 (11–34)

 

Neutrophilia

 No

173

31 (18–55)

< 0.001

 Yes

314

24 (12–39)

 

Lymphopenia

   

 No

90

36 (19–60)

< 0.001

 Yes

397

25 (13–41)

 

Anemia

 No

56

25 (13–45)

0.707

 Yes

431

26 (14–45)

 

Thrombocytopenia

 No

371

28 (14–47)

0.020

 Yes

116

20 (11–36)

 

Azotemia

 No

367

28 (14–46)

0.011

 Yes

120

20 (12–38)

 

Hypoalbuminemia

 No

176

35 (20–60)

< 0.001

 Yes

311

20 (11–37)

 

Hyperbilirubinemia

 No

341

29 (15–48)

< 0.001

 Yes

145

19 (10–32)

 

PT/INR prolongation

 No

259

29 (16–51)

< 0.001

 Yes

200

20 (10–34)

 

C-reactive proteina

 Low

239

29 (14–52)

0.007

 High

233

22 (12–38)

 

Sodium level

 Within normal range

219

28 (14–49)

< 0.001

 Hyponatremia

253

25 (13–43)

 

 Hypernatremia

15

6 (3–28)

 

Potassium level

 Within normal range

394

27 (14–46)

0.118

 Hypokalemia

65

26 (13–43)

 

 Hyperkalemia

28

19 (10–27)

 
  1. CI confidence interval, ECOG-PS Eastern Cooperative Oncology Group performance status, PT/INR prothrombin time/international normalized ratio
  2. aMedian value applied
  3. bLog-rank test